Yesterday, 9 physician groups sent a joint letter to HHS Secretary Alex Azar in which they voiced concerns about the President’s 2019 Budget and the Council of Economic Advisers’ drug plan.
Yesterday, 9 physician groups sent a joint letter to HHS Secretary Alex Azar in which they voiced concerns about the President’s 2019 Budget and the Council of Economic Advisers’ drug plan.
The groups say that the proposal to increase Medicare Part D formulary flexibility to limit or reduce coverage for patients could create problems for patients taking high cost drugs like biologics and biosimilars. This proposal would change the Part D plan formulary standards to require a minimum of 1 drug per category or class rather than the current 2. “We believe Part D benefits should not limit patients’ access to the medical therapy judged by the treating physician to be the most efficacious choice,” say the groups.
In addition, consolidating Part D drug coverage under the Medicare Part D program could also lead to access problems and force patients to use higher-cost sites of care. Given the different formulary structure and cost sharing between Part B and Part D, the groups worry that out-of-pocket costs for patients would increase, particularly for patients taking biologics prescribed by rheumatology, oncology, and neurology providers.
The groups also oppose a restructuring of Medicare Part B physician reimbursement for in-office treatment that would pay physicians 3% above the average sales price (ASP) of a drug rather than the current ASP plus 6%, and the letter urges HHS to repeal the sequester cuts to Part B drug reimbursements: “Many small and rural practices lack the ability to negotiate bulk discounts in their drug purchases and have already been forced to stop administering biologic therapies to Medicare patients,” the letter states.
Finally, the groups call for further clarification on introducing physician reimbursement that is not tied to drug prices, as physicians have no control over the cost of drugs or ancillary services, nor do they control the severity of the illnesses that these drugs treat. “Our physicians should not be penalized for rampant inflation in these sectors,” they said.
The physician groups made it clear that they support proposals that would:
The letter was signed by the American Academy of Dermatology Association, American Academy of Neurology, American Academy of Ophthalmology, American Academy of Physical Medicine and Rehabilitation, American College of Gastroenterology, American College of Rheumatology, American Gastroenterological Association, American Urological Association, and the Infectious Diseases Society of America.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.